Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (131-140 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|June 9, 2012
Anti-IL-17 mAbs herald new options in psoriasisKen Garber
Science (New York, N.Y.)|June 17, 2017
In a major shift, cancer drugs go 'tissue-agnostic'Ken Garber
Nature Biotechnology|June 8, 2017
Industry 'road tests' new wave of immune checkpointsKen Garber
Journal of the National Cancer Institute|December 5, 2002
For Bexxar, FDA meeting offers long-awaited chance at approvalKen Garber
Journal of the National Cancer Institute|June 20, 2002
Breaking the silence: the rise of epigenetic therapyKen Garber
Journal of the National Cancer Institute|July 17, 2003
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructureKen Garber
Nature Biotechnology|December 15, 2021
The PROTAC gold rushKen Garber
Nature Reviews. Drug Discovery|September 15, 2022
mRNA pioneers refocus on therapeuticsKen Garber
Nature Biotechnology|August 19, 2022
Delix Therapeutics : psychedelics without the tripKen Garber
Nature Biotechnology|December 18, 2004
NIH licensing performance under parKen Garber
Pageof 20

Showing results (131-140 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|June 9, 2012
Anti-IL-17 mAbs herald new options in psoriasisKen Garber
Science (New York, N.Y.)|June 17, 2017
In a major shift, cancer drugs go 'tissue-agnostic'Ken Garber
Nature Biotechnology|June 8, 2017
Industry 'road tests' new wave of immune checkpointsKen Garber
Journal of the National Cancer Institute|December 5, 2002
For Bexxar, FDA meeting offers long-awaited chance at approvalKen Garber
Journal of the National Cancer Institute|June 20, 2002
Breaking the silence: the rise of epigenetic therapyKen Garber
Journal of the National Cancer Institute|July 17, 2003
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructureKen Garber
Nature Biotechnology|December 15, 2021
The PROTAC gold rushKen Garber
Nature Reviews. Drug Discovery|September 15, 2022
mRNA pioneers refocus on therapeuticsKen Garber
Nature Biotechnology|August 19, 2022
Delix Therapeutics : psychedelics without the tripKen Garber
Nature Biotechnology|December 18, 2004
NIH licensing performance under parKen Garber
Pageof 20